Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alberta Health services
With
Calgary Health Region
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Stage T1 and T2 prostate cancer
Prostate specific antigen (PSA)\>=20 and Gleason score\<=6
PSA\<=15 and Gleason score 7
Signed informed consent
You may not be if
No hip prosthesis, pins or screws
No previous pelvic radiotherapy
No inflammatory bowel disease
Clareo Health | Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer
